Skip to content
Politically.com Search all
Menu

2025 · 4th Quarter (Oct 1 - Dec 31)

FRESENIUS KABI USA LLC

Filed by FRESENIUS KABI USA LLC.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
4th Quarter - Report
Posted
Jan 20, 2026
Income
Not reported
Expenses
$430,000.00
Filing UUID
8122179a-47d7-4cbb-a8b3-8980a2e58d28
Termination date
Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Drug Shortages and Medicaid Specialty Drug Pharmacy Payment Reform

HCR · Health Issues

S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act S. 1414/H.R._: Expedited Access to Biosimilars Act S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act US Drug Enforcement Administration Quota FDA/PTO Coordination USPTO Practices Most Favored Nation (MFN) Proposed Rule Biosimilar Tariffs Domestic Manufacturing Tariffs Medical Devices Generic Medicines Industry Net Effective Cost Biosimilar User Fee Act (BsUFA) Drug Shortages Domestic Manufacturing

Literal federal measure citations: S. 1954, H.R. 5526, S. 1414, S. 2276, H.R. 3269

MAN · Manufacturing

Domestic Manufacturing

CPT · Copyright/Patent/Trademark

PTAB Discretionary Denials

TRD · Trade (domestic/foreign)

Drug Shortages Domestic Manufacturing Tariffs Medical Devices Most Favored Nation (MFN) Proposed Rule Biosimilar Tariffs Generic Medicines

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.